EE05169B1 - Asendatud oksasolidinoonid ja nende kasutamine - Google Patents
Asendatud oksasolidinoonid ja nende kasutamineInfo
- Publication number
- EE05169B1 EE05169B1 EEP200200341A EEP200200341A EE05169B1 EE 05169 B1 EE05169 B1 EE 05169B1 EE P200200341 A EEP200200341 A EE P200200341A EE P200200341 A EEP200200341 A EE P200200341A EE 05169 B1 EE05169 B1 EE 05169B1
- Authority
- EE
- Estonia
- Prior art keywords
- substituted oxazolidinones
- oxazolidinones
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19962924A DE19962924A1 (de) | 1999-12-24 | 1999-12-24 | Substituierte Oxazolidinone und ihre Verwendung |
PCT/EP2000/012492 WO2001047919A1 (fr) | 1999-12-24 | 2000-12-11 | Oxazolidinones substituees et leur utilisation dans le domaine de la coagulation sanguine |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200341A EE200200341A (et) | 2003-10-15 |
EE05169B1 true EE05169B1 (et) | 2009-06-15 |
Family
ID=7934434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200341A EE05169B1 (et) | 1999-12-24 | 2000-12-11 | Asendatud oksasolidinoonid ja nende kasutamine |
Country Status (50)
Families Citing this family (247)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
DE10105989A1 (de) * | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
WO2003106413A2 (fr) * | 2001-10-18 | 2003-12-24 | Michigan State University | Procede pour l'elaboration d'oxazolidinones et procede d'utilisation correspondant |
DE10152460A1 (de) * | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
JP2005512975A (ja) | 2001-10-25 | 2005-05-12 | アストラゼネカ アクチボラグ | 抗菌薬として有用なイソキサゾリン誘導体 |
WO2003078448A1 (fr) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation de la methylation de proteines et du phosphate des phosphoproteines |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US7012088B2 (en) | 2003-02-24 | 2006-03-14 | Pharmacia & Upjohn Company | Indolone oxazolidinones and derivatives thereof |
DE10322469A1 (de) * | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
DE10336716A1 (de) * | 2003-08-11 | 2005-03-10 | Merck Patent Gmbh | Verfahren zur Herstellung von N-Aryl-morpholinonen |
DE10342570A1 (de) | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004002044A1 (de) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
EP1571154A1 (fr) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Dérivés du beta-alanine comme inhibiteurs du facteur Xa |
US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
CA2562714A1 (fr) * | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Amides d'acide thiophene-2-carboxylique substitues, leur production et leur utilisation comme medicament |
BRPI0510019A (pt) * | 2004-05-13 | 2007-09-25 | Boehringer Ingelheim Int | amidas de ácido tiofenocarboxìlico substituìdas, sua preparação e seu uso como medicamento |
JP5020073B2 (ja) | 2004-06-18 | 2012-09-05 | ミレニアム ファーマシューティカルズ インク. | 第Xa因子阻害剤 |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
WO2006008754A1 (fr) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Nouveaux intermediaires pour linezolide et composes correspondants |
PE20060619A1 (es) | 2004-07-29 | 2006-07-11 | Ferrer Int | Derivados de oxazolidinona como antibacterianos |
DE102004047840A1 (de) * | 2004-09-29 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004050283A1 (de) * | 2004-10-15 | 2006-04-27 | Lanxess Deutschland Gmbh | 4-Aminophenyl-morpholinon-Derivate und deren Herstellung |
US7645755B2 (en) | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
NZ555289A (en) | 2004-10-22 | 2010-10-29 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
JP2008527043A (ja) | 2005-01-19 | 2008-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓塞栓障害治療用のp2y1受容体阻害剤としての2−フェノキシ−n−(1,3,4−チアジアゾール−2−イル)ピリジン−3−アミン誘導体および関連化合物 |
EP1685841A1 (fr) * | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention et traitement de troubles thromboemboliques |
US8221804B2 (en) * | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
DE102005018690A1 (de) * | 2005-04-22 | 2006-10-26 | Bayer Healthcare Ag | Imino-oxazolidine und ihre Verwendung |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR20080027890A (ko) | 2005-06-27 | 2008-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전성 증상의 치료에 유용한 p2y1 수용체의 n-연결헤테로시클릭 길항제 |
US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
EP1896417B1 (fr) | 2005-06-27 | 2011-03-23 | Bristol-Myers Squibb Company | Mimetiques lineaires de l'uree antagonistes du recepteur p2y1, utilises dans le traitement des troubles thrombotiques |
PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
WO2007007588A1 (fr) * | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | Compose comportant un groupe cyclique ayant un noyau plan |
US20070032473A1 (en) * | 2005-07-19 | 2007-02-08 | Kai Gerlach | Substituted amides and their use as medicaments |
AR057976A1 (es) * | 2005-08-29 | 2008-01-09 | Boehringer Ingelheim Int | Biarilos sustituidos y su uso como medicamentos. |
DE102005045518A1 (de) * | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
RU2429236C2 (ru) * | 2005-10-04 | 2011-09-20 | Байер Шеринг Фарма Акциенгезельшафт | Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102005047564A1 (de) * | 2005-10-04 | 2007-05-31 | Bayer Healthcare Ag | Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005048824A1 (de) * | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
BRPI0617489A2 (pt) | 2005-10-18 | 2011-07-26 | Janssen Pharmaceutica Nv | compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase |
US7962847B2 (en) * | 2005-10-20 | 2011-06-14 | International Business Machines Corporation | Method for providing dynamic process step annotations |
DE102005052174A1 (de) * | 2005-11-02 | 2007-06-06 | Bayer Healthcare Ag | Phenylen-bis-oxazolidin-Derivate und ihre Verwendung |
JP2007154330A (ja) * | 2005-12-01 | 2007-06-21 | Nippon Paper Industries Co Ltd | 印刷用塗工紙 |
WO2007079186A2 (fr) * | 2005-12-30 | 2007-07-12 | Merck & Co., Inc. | Inhibiteurs de la cetp |
DE102006007146A1 (de) | 2006-02-16 | 2007-08-23 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
TW200804358A (en) | 2006-03-31 | 2008-01-16 | Res Found Itsuu Lab | Novel compound having heterocycle |
MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
US8697716B2 (en) * | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
WO2007124369A2 (fr) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Procédé d'inhibition de la kinase de c kit |
WO2007124318A1 (fr) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibiteurs de la c-fms kinase |
ES2566772T3 (es) | 2006-04-20 | 2016-04-15 | Janssen Pharmaceutica, N.V. | Inhibidores de la quinasa c-fms |
CA2651303A1 (fr) | 2006-05-05 | 2007-11-15 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de facteur xa |
DE102006025319A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Aktiengesellschaft | Substituierte Heterozyklen und ihre Verwendung |
DE102006025314A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Arylsubstituierte Heterozyklen und ihre Verwendung |
DE102006034916A1 (de) * | 2006-07-28 | 2008-01-31 | Bayer Healthcare Ag | Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten |
DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
JP5342450B2 (ja) | 2006-12-15 | 2013-11-13 | ブリストル−マイヤーズ スクイブ カンパニー | 第XIa因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ |
PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
US20080293704A1 (en) * | 2007-01-05 | 2008-11-27 | Millennium Pharmaceuticals, Inc. | FACTOR Xa INHIBITORS |
EP2141154A4 (fr) | 2007-03-30 | 2011-06-01 | Inst Med Molecular Design Inc | Dérivé d'oxazolidinone ayant une activité inhibitrice sur la 11 -hydroxystéroïde déshydrogénase de type i |
DE102007018662A1 (de) | 2007-04-20 | 2008-10-23 | Bayer Healthcare Ag | Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie |
MX2009011089A (es) | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
KR101009594B1 (ko) | 2007-05-09 | 2011-01-20 | 주식회사 레고켐 바이오사이언스 | P4 위치에 사이클릭 아미딘을 가지는 FXa 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물 |
WO2008140220A1 (fr) * | 2007-05-09 | 2008-11-20 | Legochem Bioscience Ltd. | Inhibiteurs du facteur xa comprenant des amidines cycliques en tant que sous-unité p4, leurs procédés de préparation, et compositions pharmaceutiques et dérivés de ceux-ci |
DE102007028318A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Oxazolidinone zur Behandlung und Prophylaxe von Sepsis |
DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007037373A1 (de) | 2007-08-06 | 2009-02-19 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
WO2009018807A1 (fr) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Oxazolidinones utilisées comme inhibiteurs du facteur xa, procédé pour leur production et leur utilisation thérapeutique |
US20090076264A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched rivaroxaban |
CN101883768A (zh) | 2007-10-02 | 2010-11-10 | 财团法人乙卯研究所 | 具有7元杂环的噁唑烷酮衍生物 |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
WO2009063028A2 (fr) | 2007-11-15 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Amides substitués, leur fabrication et utilisation sous forme de médicaments |
JP2011506363A (ja) * | 2007-12-11 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全の処置および/または予防用のオキサゾリジノン類 |
JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
JP5607025B2 (ja) | 2008-04-21 | 2014-10-15 | シグナム バイオサイエンシーズ, インコーポレイテッド | 化合物、組成物およびそれらを作製する方法 |
DE102008028071A1 (de) * | 2008-06-12 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure |
EP2138178A1 (fr) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones pour le traitement de maladie pulmonaire obstructive chronique (MPOC) et/ou de l'asthme |
KR100898361B1 (ko) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | P4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 FXa 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물 |
EP2140866A1 (fr) * | 2008-07-04 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidinones pour le traitement d'états inflammatoires du tractus gastro-intestinal |
JP2011527297A (ja) | 2008-07-08 | 2011-10-27 | ラーツイオフアルム・ゲー・エム・ベー・ハー | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドを含む医薬組成物 |
KR101023174B1 (ko) * | 2008-09-24 | 2011-03-18 | 주식회사 레고켐 바이오사이언스 | 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
PE20120003A1 (es) * | 2009-01-30 | 2012-02-12 | Glaxosmithkline Llc | Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino |
US7816355B1 (en) * | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
ES2606127T5 (es) | 2009-06-18 | 2020-02-17 | Krka Tovarna Zdravil D D Novo Mesto | Composición farmacéutica sólida que comprende rivaroxabán |
EP2266541A1 (fr) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Composition pharmaceutique solide comprenant du rivaroxaban |
KR101037052B1 (ko) * | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | 5-클로로-n-(((5s)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4h)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체 |
KR101037051B1 (ko) * | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | (s)-5-클로로-n-((3-(4-(5,6-다이하이드로-4h-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법 |
EA031064B2 (ru) * | 2009-07-31 | 2020-07-01 | КРКА, д.д., НОВО МЕСТО | Способы кристаллизации ривароксабана |
WO2011042156A1 (fr) | 2009-10-06 | 2011-04-14 | Ratiopharm Gmbh | Compositions pharmaceutiques contenant du rivaroxaban |
EP2308472A1 (fr) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Compositions pharmaceutiques comportant du rivaroxaban |
WO2011061760A1 (fr) * | 2009-11-18 | 2011-05-26 | Cadila Healthcare Limited | Nouveaux agents antithrombotiques |
EP2513094B1 (fr) | 2009-12-17 | 2015-12-16 | Millennium Pharmaceuticals, Inc. | Sels et formes cristallines d'inhibiteur de facteur xa |
US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
CN102822167A (zh) * | 2010-01-04 | 2012-12-12 | 埃南蒂亚有限公司 | 用于制备利伐沙班的方法及其中间体 |
EP2354128A1 (fr) * | 2010-02-10 | 2011-08-10 | Sandoz Ag | Procédé pour la préparation de rivaroxaban |
ES2822130T3 (es) | 2010-02-11 | 2021-04-29 | Bristol Myers Squibb Co | Macrociclos como inhibidores del factor XIa |
EA015918B1 (ru) | 2010-03-03 | 2011-12-30 | Дмитрий Геннадьевич ТОВБИН | УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa |
DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
DE102010028362A1 (de) | 2010-04-29 | 2011-11-03 | Bayer Schering Pharma Aktiengesellschaft | Herstellverfahren |
KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
EP2388260A1 (fr) | 2010-05-21 | 2011-11-23 | Archimica GmbH | Procédé de fabrication pour un inhibiteur d'un facteur de coagulation sanguine |
CN102311400A (zh) * | 2010-06-29 | 2012-01-11 | 翔真生物科技股份有限公司 | 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法 |
EP2404920A1 (fr) | 2010-07-06 | 2012-01-11 | Sandoz AG | Form cristalline de Rivaroxaban dihydrate |
US20130253187A1 (en) * | 2010-09-14 | 2013-09-26 | Medichem, S.A. | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative |
CZ2010714A3 (cs) | 2010-09-30 | 2012-04-11 | Farmak, A. S. | Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote |
EP2630143B1 (fr) * | 2010-10-18 | 2017-11-29 | Apotex Pharmachem Inc. | Procédés de préparation de rivaroxaban et ses intermédiaires |
CN102464658B (zh) * | 2010-11-03 | 2014-04-16 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
DE102010063127A1 (de) | 2010-12-15 | 2012-06-21 | Bayer Schering Pharma Aktiengesellschaft | Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US20140050743A1 (en) | 2011-01-19 | 2014-02-20 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
CN102199150A (zh) * | 2011-04-01 | 2011-09-28 | 中国药科大学 | 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途 |
EP2697209B1 (fr) | 2011-04-11 | 2015-09-23 | Sandoz AG | Procédé de préparation d'oxazolidinones substituées |
WO2012153155A1 (fr) | 2011-05-06 | 2012-11-15 | Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság | Procédé de préparation d'un principe actif pharmaceutique, et intermédiaires formés lors dudit procédé |
WO2012156983A1 (fr) * | 2011-05-16 | 2012-11-22 | Symed Labs Limited | Procédés pour la préparation de 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]-1,3-oxazolidin-5-yl}méthyl)-2-thiophènecarboxamide |
ES2395304B1 (es) * | 2011-05-20 | 2014-01-16 | Interquim, S.A. | Procedimiento de obtención de una tiofen-2-carboxamida. |
CN102796092B (zh) * | 2011-05-24 | 2015-04-08 | 北大方正集团有限公司 | 噁唑烷酮衍生物及其制备方法和应用 |
CN102796091A (zh) * | 2011-05-24 | 2012-11-28 | 北大方正集团有限公司 | 取代的噁唑烷酮化合物及其制备方法和应用 |
CN102320988B (zh) * | 2011-06-03 | 2014-04-09 | 中国科学院上海有机化学研究所 | 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途 |
CN102827154B (zh) * | 2011-06-14 | 2015-04-22 | 上海科胜药物研发有限公司 | 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
WO2013098833A2 (fr) | 2011-09-08 | 2013-07-04 | Cadila Healthcare Limited | Procédés et intermédiaires destinés à la préparation de rivaroxaban |
EP2573084A1 (fr) | 2011-09-22 | 2013-03-27 | Enantia, S.L. | Nouvelles formes cristallines de rivaroxaban et leurs procédés de préparation |
WO2013046211A1 (fr) * | 2011-09-27 | 2013-04-04 | Symed Labs Limited | Procédés de préparation du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morpholinyl) phényl]-1,3-oxazolidin-5-yl}méthyl)-2-thiophène-carbomaxide et de ses intermédiaires |
HU230734B1 (hu) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok |
WO2013053739A1 (fr) | 2011-10-10 | 2013-04-18 | Laboratorios Lesvi, S. L. | Procédé de préparation d'inhibiteurs du facteur xa |
EP2766373B1 (fr) * | 2011-10-11 | 2016-08-17 | Council of Scientific & Industrial Research | Sila-analogues de dérivés d'oxazolidinone et synthèse de ceux-ci |
IN2014CN02805A (fr) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
TWI633091B (zh) | 2011-10-14 | 2018-08-21 | Bristol-Myers Squibb Company | 作為因子xia抑制劑之經取代四氫異喹啉化合物 |
ES2699226T3 (es) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
CN102408420B (zh) * | 2011-10-19 | 2014-10-22 | 汕头经济特区鮀滨制药厂 | 一种利伐沙班及其中间体的制备方法以及中间体化合物 |
EP2812329A2 (fr) | 2012-02-06 | 2014-12-17 | Megafine Pharma (P) Ltd. | Procédé de préparation de rivaroxaban et de ses intermédiaires |
CZ2012111A3 (cs) | 2012-02-16 | 2013-08-28 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu |
CZ2012114A3 (cs) | 2012-02-17 | 2013-02-20 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu |
CN103288814B (zh) | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
WO2013151719A2 (fr) * | 2012-04-05 | 2013-10-10 | Scifluor Life Sciences, Llc | Dérivés oxazolidinone fluorés |
WO2013152168A1 (fr) | 2012-04-06 | 2013-10-10 | Indiana University Research And Technology Corporation | Procédés de préparation du rivaroxaban |
WO2013156936A1 (fr) | 2012-04-16 | 2013-10-24 | Ranbaxy Laboratories Limited | Procédé pour la préparation de rivaroxaban et d'intermédiaires de celui-ci |
BR112014027248B1 (pt) * | 2012-05-02 | 2021-01-26 | Symed Labs Limited | processo em um único recipiente para preparar rivaroxaban |
WO2013175431A1 (fr) | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Procédé pour la préparation de rivaroxaban |
CN102746287B (zh) * | 2012-06-21 | 2014-05-28 | 成都苑东药业有限公司 | 一种恶唑烷酮化合物及其制备方法 |
UY34856A (es) | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
CN102757424B (zh) * | 2012-07-09 | 2014-10-15 | 云南大学 | 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法 |
CN102746288B (zh) * | 2012-07-24 | 2015-04-08 | 常州制药厂有限公司 | 一种抗凝血药及其关键中间体的制备方法 |
RS55975B1 (sr) | 2012-08-03 | 2017-09-29 | Bristol Myers Squibb Co | Dihidropiridon p1 kao inhibitori xia faktora |
PL2882734T3 (pl) | 2012-08-03 | 2017-05-31 | Bristol-Myers Squibb Company | Dihydropirydon jako inhibitory czynnika XIA |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
CN103626749A (zh) * | 2012-08-21 | 2014-03-12 | 苏州泽璟生物制药有限公司 | 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途 |
EP2900663A2 (fr) | 2012-09-26 | 2015-08-05 | Ranbaxy Laboratories Limited | Procédé pour la préparation de rivaroxaban |
CN103864773B (zh) * | 2012-12-13 | 2017-03-15 | 北京藏卫信康医药研发有限公司 | 利伐沙班及其中间体的制备方法 |
EP3309158B1 (fr) | 2012-12-21 | 2022-03-16 | Krka, tovarna zdravil, d.d. | Forme cristalline k du rivaroxaban et procédé de préparation |
CA2883323A1 (fr) * | 2012-12-26 | 2014-07-03 | Wanbury Ltd. | Derive aldehyde d'oxalidinones substituees |
WO2014102820A2 (fr) | 2012-12-26 | 2014-07-03 | Wanbury Ltd. | Intermédiaire du rivaroxaban et sa préparation |
WO2014160668A1 (fr) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia |
WO2014155259A2 (fr) * | 2013-03-25 | 2014-10-02 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Procédé pour la préparation de rivaroxaban |
CN104098556B (zh) * | 2013-04-09 | 2019-01-08 | 浙江九洲药物科技有限公司 | 一种利伐沙班的合成工艺 |
CN104163819A (zh) * | 2013-05-17 | 2014-11-26 | 天津药物研究院 | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 |
CN103242307B (zh) * | 2013-05-17 | 2015-08-12 | 天津药物研究院有限公司 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
WO2014195244A1 (fr) * | 2013-06-03 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Triazolopyridines utilisées comme inhibiteurs de la thrombine pour traiter des maladies thromboemboliques |
JP2016520110A (ja) * | 2013-06-03 | 2016-07-11 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ベンゾキサゾール |
UY35592A (es) | 2013-06-03 | 2014-12-31 | Bayer Pharma AG | Benzoxazoles sustituidos |
WO2015011617A1 (fr) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Procédé pour la préparation de rivaroxaban |
IN2013MU02699A (fr) | 2013-08-19 | 2015-06-19 | Amneal Pharmaceuticals Llc | |
IN2014MU00072A (fr) | 2014-01-08 | 2015-08-21 | Wockhardt Ltd | |
WO2015111076A2 (fr) * | 2014-01-23 | 2015-07-30 | Symed Labs Limited | Procédés améliorés pour la préparation d'une modification cristalline i de rivaroxaban à haute pureté |
DK3099687T3 (en) | 2014-01-31 | 2018-10-22 | Bristol Myers Squibb Co | MACROCYCLES WITH HETEROCYCLIC P2 'GROUPS AS FACTOR XIA INHIBITORS |
NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
WO2015124995A1 (fr) | 2014-02-19 | 2015-08-27 | Aurobindo Pharma Ltd | Formes galéniques solides de rivaroxaban |
WO2015155307A1 (fr) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de pompe à protons |
CN104974149B (zh) * | 2014-04-14 | 2018-05-01 | 北大方正集团有限公司 | 一种利伐沙班的制备方法 |
CN105085371B (zh) * | 2014-04-22 | 2017-06-16 | 北大方正集团有限公司 | (s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法 |
KR101499867B1 (ko) * | 2014-04-22 | 2015-03-06 | 에스케이케미칼주식회사 | 활성 성분 (i) 함유 조성물 및 이의 제조 방법 |
CN105085370B (zh) * | 2014-04-22 | 2017-04-12 | 北大方正集团有限公司 | (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法 |
EP2942058A1 (fr) | 2014-05-09 | 2015-11-11 | Sanovel Ilac Sanayi ve Ticaret A.S. | Combinaisons pharmaceutiques de rivaroxaban et des antagonistes du récepteur d'histamine H2 |
CN104031036A (zh) * | 2014-05-16 | 2014-09-10 | 南通常佑药业科技有限公司 | 一种利伐沙班的制备方法 |
EP3147283B1 (fr) | 2014-05-22 | 2022-08-17 | North China Pharmaceutical Company., Ltd. | Composé hydrazine inhibiteur du facteur xa de coagulation sanguine |
CN103980221B (zh) * | 2014-05-26 | 2016-03-23 | 山东康美乐医药科技有限公司 | 4-(硝基苯基)-3-吗啉酮的制备方法及利用其制备利伐沙班的方法 |
DE102014108210A1 (de) * | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
WO2015198259A1 (fr) | 2014-06-26 | 2015-12-30 | Erregierre S.P.A. | Procédé de synthèse de rivaroxaban et intermédiaire pour la production de celui-ci |
TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環(4.5)癸烷衍生物 |
CA2955071A1 (fr) | 2014-07-15 | 2016-01-21 | Grunenthal Gmbh | Derives d'azaspiro(4,5)decane substitues |
CN104086539A (zh) * | 2014-07-17 | 2014-10-08 | 天津炜捷制药有限公司 | 一种利伐沙班的制备方法 |
WO2016030669A1 (fr) | 2014-08-25 | 2016-03-03 | Cipla Limited | Procédé de préparation du rivaroxaban |
NO2721243T3 (fr) | 2014-10-01 | 2018-10-20 | ||
CN104356124A (zh) * | 2014-10-30 | 2015-02-18 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其组合物和用途 |
CN104402876A (zh) * | 2014-11-25 | 2015-03-11 | 沈阳药科大学 | 噁唑烷酮类化合物及其应用 |
CN104447728B (zh) * | 2014-12-05 | 2017-01-04 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104478866B (zh) * | 2014-12-05 | 2017-07-07 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104447729A (zh) * | 2014-12-05 | 2015-03-25 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104478869B (zh) * | 2014-12-05 | 2017-04-12 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104496978A (zh) * | 2014-12-09 | 2015-04-08 | 广东东阳光药业有限公司 | 取代噁唑烷酮类化合物及其使用方法和用途 |
CN104530029B (zh) * | 2014-12-09 | 2017-04-12 | 广东东阳光药业有限公司 | 作为Xa因子抑制剂的杂环化合物及其使用方法和用途 |
CN104497008B (zh) * | 2014-12-09 | 2016-11-16 | 广东东阳光药业有限公司 | 取代噁唑烷酮类化合物及其使用方法和用途 |
CN104530031A (zh) * | 2014-12-10 | 2015-04-22 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104530080B (zh) * | 2014-12-10 | 2017-01-11 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN104530030A (zh) * | 2014-12-10 | 2015-04-22 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
CN105777734A (zh) * | 2014-12-22 | 2016-07-20 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体的合成方法 |
CN104557900A (zh) * | 2014-12-23 | 2015-04-29 | 中国药科大学 | 噁唑烷酮类化合物及其制备方法与医药用途 |
CN105820161A (zh) * | 2015-01-08 | 2016-08-03 | 常州方楠医药技术有限公司 | 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法 |
TR201501970A2 (en) | 2015-02-19 | 2016-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of dronedarone. |
CR20170426A (es) | 2015-03-20 | 2017-10-23 | Hoffmann La Roche | Inhibidores de bace 1 |
WO2016150937A1 (fr) | 2015-03-25 | 2016-09-29 | Lonza Ltd | Procédé de préparation de chlorures de thiophènecarbonyle |
CN104926807B (zh) * | 2015-06-04 | 2017-10-31 | 沈阳药科大学 | 一种利伐沙班相关物质“二胺”及其合成方法 |
JP6742348B2 (ja) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としてのジアミド大員環 |
WO2017019821A1 (fr) | 2015-07-29 | 2017-02-02 | Bristol-Myers Squibb Company | Nouveau macrocycle de facteur xia portant un groupe p2' non aromatique |
WO2017023992A1 (fr) | 2015-08-05 | 2017-02-09 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de fxia dérivés de glycine substitués |
CN108290877A (zh) * | 2015-11-04 | 2018-07-17 | 隆萨有限公司 | 用草酰氯制备噻吩-2-甲酰氯的方法 |
PL3377176T3 (pl) | 2016-02-23 | 2022-02-28 | Morgandane Scientific, LLC | Sposób leczenia pacjentów otrzymujących jednocześnie rywaroksaban i werapamil |
EP3423458A1 (fr) | 2016-03-02 | 2019-01-09 | Bristol-Myers Squibb Company | Macrocycles diamide présentant une activité inhibitrice du facteur xia |
EP3263096A1 (fr) | 2016-06-28 | 2018-01-03 | Sanovel Ilac Sanayi ve Ticaret A.S. | Composition pharmaceutique en capsule de rivaroxaban |
CN106588905A (zh) * | 2016-12-13 | 2017-04-26 | 重庆英斯凯化工有限公司 | 一种利伐沙班中间体的制备方法 |
WO2018127762A1 (fr) * | 2017-01-04 | 2018-07-12 | Unichem Laboratories Ltd | Procédé amélioré pour la préparation de rivaroxaban impliquant un nouvel intermédiaire |
CN107586291B (zh) * | 2017-11-03 | 2019-08-20 | 梯尔希(南京)药物研发有限公司 | 一种利伐沙班代谢物5的合成方法 |
CN107857739A (zh) * | 2017-11-14 | 2018-03-30 | 安徽华胜医药科技有限公司 | 一种氘代利伐沙班关键中间体及其制备方法 |
CN107857761A (zh) * | 2017-11-14 | 2018-03-30 | 安徽华胜医药科技有限公司 | 一种氘代利伐沙班及其制备方法 |
CN108164519A (zh) * | 2017-12-28 | 2018-06-15 | 江苏悦兴医药技术有限公司 | 利伐沙班工艺杂质的合成方法 |
EP3505160A1 (fr) | 2017-12-31 | 2019-07-03 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | Préparation d'une composition pharmaceutique solide comprenant du rivaroxaban et sa production |
HU231119B1 (hu) | 2018-01-12 | 2020-11-30 | Richter Gedeon Nyrt. | Eljárás 4-(4-aminofenil)morfolin-3-on előállítására |
US10828310B2 (en) | 2018-02-02 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Reducing the risk of cardiovascular events |
GB201807014D0 (en) | 2018-04-30 | 2018-06-13 | Univ Leeds Innovations Ltd | Factor xlla inhibitors |
CN108546265A (zh) * | 2018-06-22 | 2018-09-18 | 苏州中联化学制药有限公司 | 一种利伐沙班中间体的合成方法 |
US10722486B2 (en) | 2018-08-13 | 2020-07-28 | Morgandane Scientific, LLC | Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil |
CN110054621A (zh) * | 2019-03-12 | 2019-07-26 | 浙江天宇药业股份有限公司 | 一种利伐沙班中间体的制备方法 |
CN110615756A (zh) * | 2019-06-28 | 2019-12-27 | 南京红杉生物科技有限公司 | 1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用 |
US11608320B2 (en) | 2020-02-02 | 2023-03-21 | Kuwait University | Oxazolidinone hydroxamic acid derivatives |
CN111253383A (zh) * | 2020-03-27 | 2020-06-09 | 南京国星生物技术研究院有限公司 | 一种利伐沙班的合成方法 |
CN112159402B (zh) * | 2020-10-28 | 2022-04-05 | 南京法恩化学有限公司 | 一种利伐沙班的制备方法 |
GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
EP4070658A1 (fr) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Utilisation de composés anticoagulants comme rodenticides |
GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
CN115260117B (zh) * | 2022-08-09 | 2024-05-28 | 江苏法安德医药科技有限公司 | 一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1035546B (de) | 1955-02-16 | 1958-07-31 | Max Ruf | Torbegrenzung fuer Ballspiele |
US2811555A (en) | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
ES8506659A1 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
CA1317594C (fr) | 1987-10-21 | 1993-05-11 | Chung-Ho Park | Derives aminomethyloxooxazolidinylethenylbenzene, utiles comme agents antibacteriens |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
KR100257418B1 (ko) * | 1991-11-01 | 2000-05-15 | 로렌스 티. 마이젠헬더 | 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논 |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5349045A (en) | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
ATE181735T1 (de) | 1993-05-01 | 1999-07-15 | Merck Patent Gmbh | Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
NZ302844A (en) | 1995-02-03 | 1999-06-29 | Upjohn Co | Antimicrobial hetero-aromatic ring substituted phenyloxazolidinones |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
DE19524765A1 (de) | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
BR9610474A (pt) | 1995-09-01 | 1999-03-02 | Upjohn Co | Feniloxazolidinonas tendo uma ligação c-c a anéis heterocíclicos com 4-8 membros |
US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
DE19601264A1 (de) | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
CN1155409C (zh) | 1996-07-15 | 2004-06-30 | 三共株式会社 | 用于预防和治疗动脉硬化的药物组合物 |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
JP2002501530A (ja) | 1997-05-30 | 2002-01-15 | ファルマシア・アンド・アップジョン・カンパニー | チオカルボニル官能基を有するオキサゾリジノン抗菌剤 |
CN1211384C (zh) | 1997-07-11 | 2005-07-20 | 法玛西雅厄普约翰美国公司 | 噻二唑基和噁二唑基苯基噁唑烷酮抗菌剂 |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
ES2207010T3 (es) | 1997-11-12 | 2004-05-16 | PHARMACIA & UPJOHN COMPANY | Derivados de oxazolidinona y composiciones farmaceuticas. |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
DE19802239A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Neue mit Bicyclen substituierte Oxazolidinone |
CN1288462A (zh) | 1998-01-23 | 2001-03-21 | 法玛西雅厄普约翰美国公司 | 噁唑烷酮组合库、组合物和制备方法 |
YU47600A (sh) | 1998-01-27 | 2002-09-19 | Aventis Pharmaceuticals Products Inc. | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa |
DE19805117A1 (de) | 1998-02-09 | 1999-08-12 | Bayer Ag | Neue Oxazolidinone mit azolhaltigen Tricyclen |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
EA003458B1 (ru) | 1998-05-18 | 2003-06-26 | Фармация Энд Апджон Компани | Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина |
DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
PE20010851A1 (es) | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
CZ20022142A3 (cs) | 1999-12-21 | 2002-11-13 | Pharmacia & Upjohn Company | Oxazolidinony mající sulfoximinovou funkční skupinu |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
AU2225901A (en) | 1999-12-28 | 2001-07-09 | Ajinomoto Co., Inc. | Aspartame derivative crystals |
DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10152460A1 (de) | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (fr) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention et traitement de troubles thromboemboliques |
AU2006214534B2 (en) | 2005-02-14 | 2012-07-19 | Epitopix, Llc | Polypeptides from Staphylococcus aureus and methods of use |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
RU2429236C2 (ru) | 2005-10-04 | 2011-09-20 | Байер Шеринг Фарма Акциенгезельшафт | Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида |
DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
KR101378695B1 (ko) * | 2007-04-18 | 2014-03-31 | 삼성전자주식회사 | 통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치 |
-
1999
- 1999-12-24 DE DE19962924A patent/DE19962924A1/de not_active Withdrawn
-
2000
- 2000-11-29 HN HN2000000267A patent/HN2000000267A/es unknown
- 2000-12-11 TR TR2004/01314T patent/TR200401314T2/xx unknown
- 2000-12-11 ES ES00993610T patent/ES2237497T3/es not_active Expired - Lifetime
- 2000-12-11 DK DK04027037.3T patent/DK1526132T3/da active
- 2000-12-11 PT PT00993610T patent/PT1261606E/pt unknown
- 2000-12-11 NZ NZ537058A patent/NZ537058A/en not_active IP Right Cessation
- 2000-12-11 SI SI200031079T patent/SI1526132T1/sl unknown
- 2000-12-11 DE DE50009607T patent/DE50009607D1/de not_active Expired - Lifetime
- 2000-12-11 PL PL355665A patent/PL200413B1/pl unknown
- 2000-12-11 UA UA2002076161A patent/UA73339C2/uk unknown
- 2000-12-11 SG SG200403830-3A patent/SG130939A1/en unknown
- 2000-12-11 SK SK908-2002A patent/SK287272B6/sk not_active IP Right Cessation
- 2000-12-11 NZ NZ519730A patent/NZ519730A/en not_active IP Right Cessation
- 2000-12-11 US US10/181,051 patent/US7157456B2/en active Active
- 2000-12-11 BR BRPI0017050-0A patent/BR0017050B1/pt active IP Right Grant
- 2000-12-11 JP JP2001549389A patent/JP4143297B2/ja not_active Expired - Lifetime
- 2000-12-11 PT PT40270373T patent/PT1526132E/pt unknown
- 2000-12-11 MX MXPA02006241A patent/MXPA02006241A/es active IP Right Grant
- 2000-12-11 CZ CZ20022202A patent/CZ301432B6/cs not_active IP Right Cessation
- 2000-12-11 KR KR1020027008172A patent/KR100804932B1/ko active IP Right Review Request
- 2000-12-11 DE DE122009000014C patent/DE122009000014I1/de active Pending
- 2000-12-11 EE EEP200200341A patent/EE05169B1/xx active Protection Beyond IP Right Term
- 2000-12-11 RU RU2002120456/04A patent/RU2297415C2/ru active Protection Beyond IP Right Term
- 2000-12-11 DK DK00993610T patent/DK1261606T3/da active
- 2000-12-11 SI SI200030679T patent/SI1261606T1/xx unknown
- 2000-12-11 PL PL382243A patent/PL201121B1/pl unknown
- 2000-12-11 CN CN2006100819193A patent/CN1900074B/zh not_active Expired - Lifetime
- 2000-12-11 WO PCT/EP2000/012492 patent/WO2001047919A1/fr active Application Filing
- 2000-12-11 ES ES04027037.3T patent/ES2457021T3/es not_active Expired - Lifetime
- 2000-12-11 EP EP00993610A patent/EP1261606B1/fr not_active Expired - Lifetime
- 2000-12-11 KR KR1020077020537A patent/KR20070094672A/ko not_active Application Discontinuation
- 2000-12-11 CN CNB008189668A patent/CN1262551C/zh not_active Expired - Lifetime
- 2000-12-11 AT AT00993610T patent/ATE289605T1/de active
- 2000-12-11 IL IL14989600A patent/IL149896A0/xx active Protection Beyond IP Right Term
- 2000-12-11 HU HU0203902A patent/HU226522B1/hu active Protection Beyond IP Right Term
- 2000-12-11 EP EP04027037.3A patent/EP1526132B1/fr not_active Expired - Lifetime
- 2000-12-11 CA CA002396561A patent/CA2396561C/fr not_active Expired - Lifetime
- 2000-12-11 CN CNB2005101271139A patent/CN100549008C/zh not_active Expired - Lifetime
- 2000-12-11 KR KR1020077008192A patent/KR20070044075A/ko not_active Application Discontinuation
- 2000-12-11 TR TR2002/01636T patent/TR200201636T2/xx unknown
- 2000-12-11 AU AU28414/01A patent/AU775126C/en not_active Expired
- 2000-12-18 AR ARP000106733A patent/AR032436A1/es active IP Right Grant
- 2000-12-19 GT GT200000216A patent/GT200000216A/es unknown
- 2000-12-20 TW TW083120747A patent/TWI277615B/zh not_active IP Right Cessation
- 2000-12-20 TW TW089127307A patent/TWI226330B/zh active
- 2000-12-20 DO DO2000000114A patent/DOP2000000114A/es unknown
- 2000-12-21 SV SV2000000245A patent/SV2002000245A/es active IP Right Grant
- 2000-12-22 CO CO00097415A patent/CO5251440A1/es active IP Right Grant
- 2000-12-22 MY MYPI20006170A patent/MY140488A/en unknown
- 2000-12-22 PE PE2000001388A patent/PE20010963A1/es not_active IP Right Cessation
-
2002
- 2002-05-27 ZA ZA200204188A patent/ZA200204188B/en unknown
- 2002-06-07 CU CU20020114A patent/CU23208A3/es unknown
- 2002-06-14 BG BG106825A patent/BG65683B1/bg unknown
- 2002-06-21 NO NO20023043A patent/NO323699B1/no not_active IP Right Cessation
- 2002-06-21 MA MA26708A patent/MA25646A1/fr unknown
- 2002-07-23 HR HR20020617A patent/HRP20020617B1/xx not_active IP Right Cessation
-
2004
- 2004-01-20 HK HK06112529.9A patent/HK1092140A1/xx not_active IP Right Cessation
- 2004-01-20 HK HK04100440A patent/HK1057556A1/xx not_active IP Right Cessation
- 2004-10-13 CU CU20040221A patent/CU23423B7/es unknown
- 2004-10-13 AU AU2004218729A patent/AU2004218729A1/en not_active Withdrawn
- 2004-12-10 JP JP2004358908A patent/JP5190173B2/ja not_active Expired - Lifetime
-
2006
- 2006-07-18 HR HRP20060251AA patent/HRP20060251B1/hr not_active IP Right Cessation
- 2006-07-27 US US11/460,529 patent/US7592339B2/en not_active Expired - Fee Related
-
2007
- 2007-02-20 NO NO20070981A patent/NO20070981L/no not_active Application Discontinuation
- 2007-07-17 HK HK07107638.6A patent/HK1103235A1/xx not_active IP Right Cessation
- 2007-10-31 US US11/932,082 patent/US7576111B2/en not_active Expired - Fee Related
-
2008
- 2008-01-11 DO DO2008000001A patent/DOP2008000001A/es unknown
- 2008-02-07 US US12/027,553 patent/US7585860B2/en not_active Expired - Fee Related
- 2008-11-19 LU LU91497C patent/LU91497I2/fr unknown
- 2008-11-25 NL NL300370C patent/NL300370I2/nl unknown
- 2008-12-02 CY CY200800019C patent/CY2008019I1/el unknown
- 2008-12-04 LT LTPA2008018C patent/LTC1261606I2/lt unknown
- 2008-12-10 BE BE2008C046C patent/BE2008C046I2/fr unknown
- 2008-12-11 FR FR08C0051C patent/FR08C0051I2/fr active Active
-
2009
- 2009-01-08 NO NO2009001C patent/NO2009001I1/no not_active IP Right Cessation
- 2009-06-30 US US12/494,879 patent/US8129378B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 IL IL205242A patent/IL205242A/en unknown
-
2012
- 2012-01-27 US US13/360,107 patent/US8530505B2/en not_active Expired - Fee Related
- 2012-06-22 UY UY0001034152A patent/UY34152A/es not_active Application Discontinuation
-
2013
- 2013-08-07 US US13/961,264 patent/US8822458B2/en not_active Expired - Fee Related
-
2014
- 2014-05-29 CY CY20141100383T patent/CY1115117T1/el unknown
- 2014-07-21 US US14/336,379 patent/US20150166568A1/en not_active Abandoned
-
2021
- 2021-02-25 NO NO2021009C patent/NO2021009I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05169B1 (et) | Asendatud oksasolidinoonid ja nende kasutamine | |
EE200200251A (et) | Uued N-asabitsükloamiidi derivaadid ja nende kasutamine | |
EE200200175A (et) | Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine | |
ID26056A (id) | Popok sekali pakai | |
ID26389A (id) | Popok sekali pakai | |
DE60044873D1 (de) | Orientierte biopolymermembrane | |
NO20021116D0 (no) | Ny sammensetning | |
IS6120A (is) | Lyfjablanda | |
ID25977A (id) | Popok sekali pakai | |
ID24555A (id) | Popok sekali pakai | |
ID23076A (id) | Popok sekali pakai | |
EE200100373A (et) | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena | |
ID26608A (id) | Komposit-komposit polimer-pigmen | |
DE60008638D1 (de) | Förderbandabstreicher | |
DE60034061D1 (de) | 4-pyrimidinyl-n-acyl-l-phenylanine | |
NO20021115L (no) | Ny sammensetning | |
ID27776A (id) | Bahan dengan efek antidepresan | |
ID23083A (id) | Popok sekali pakai | |
DE60043058D1 (de) | Dentalwerkstoffe | |
DE69943245D1 (de) | Gaserzeugende zusammensetzung | |
ID25571A (id) | Popok sekali pakai | |
ID24782A (id) | Popok sekali pakai | |
DE60032898D1 (de) | Arylthiazolidindion- und aryloxazolidinderivate | |
FIU990494U0 (fi) | Uusi koostumus | |
DE60020682D1 (de) | Resorcinenthaltende zusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HB1A | Correction of owner name or address | ||
GB1A | Change in the ownership or in the address of the owner | ||
GB1A | Change in the ownership or in the address of the owner | ||
AA1Y | Spc filed |
Free format text: PRODUCT NAME: XARELTO-RIVAROXABAN Spc suppl protection certif: C20090004 Filing date: 20090812 |
|
FG1Y | Spc granted |
Free format text: PRODCUT NAME: XARELTO-RIVAROXABAN Spc suppl protection certif: C20090004 00025 Filing date: 20090812 Extension date: 20230930 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
GB1A | Change in the ownership or in the address of the owner | ||
SPCE | Request for extension of supplementary protection certificate filed [paediatric extension] |
Free format text: PRODUCT NAME: XARELTO-RIVAROXABAN; AUTHORISATION NUMBER/DATE: EMA/207785/2021, 13.04.2021 Spc suppl protection certif: C20090004 00025 Extension date: 20240402 |
|
SPCT | Party data change related to a supplementary protection certificate |
Free format text: PARTY DATA CHANGE RELATED TO A GRANTED SPC Spc suppl protection certif: 00025 |